期刊
JOURNAL OF MOLECULAR DIAGNOSTICS
卷 22, 期 3, 页码 338-345出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jmoldx.2019.11.004
关键词
-
类别
资金
- Department of Pathology, Oregon Health & Science University
- Knight Cancer Institute, Oregon Health & Science University
Myeloid sarcoma is a rare, architecture-effacing proliferation of myeloid blasts localized to an extra medullary site, with or without concurrent bone marrow involvement. Clonal heterogeneity results from acquisition of somatic mutations within different subclones of leukemic cells. It was hypothesized that clonal heterogeneity between myeloid sarcomas and concurrent bone marrow biopsies might be present, given their differing biological features and microenvironment. High-throughput sequencing of the largest series (n = 24) of paired myeloid sarcomas and bone marrow biopsies was performed. One third of myeloid sarcomas (8/24) showed discordant molecular profiles, and 75% (n = 6) of these cases had discordant mutations in genes with prognostic significance or molecularly targeted therapies. Patients with molecularly discordant myeloid sarcoma had significantly worse overall survival (median survival, 195 days versus not reached, hazard ratio, 3.3, P < 0.05). Further investigation into molecular discordance between myeloid sarcoma and concurrent bone marrow biopsies may help in understanding clonal evolution of myeloid neoplasms and mechanisms regulating extramedullary blast localization.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据